Breaking News

Cempra, Macrolide in Mfg. Process Development Pact

February 1, 2016

Aims to develop a fully synthetic manufacturing process for solithromycin

Cempra, Inc. and Macrolide Pharmaceuticals, Inc. have entered an agreement under which Macrolide will apply its synthesis technology to provide Cempra with a fully synthetic process for its late-stage investigational macrolide antibiotic, solithromycin for the treatment of community acquired bacterial pneumonia.
 
Solithromycin is currently manufactured using clarithromycin, a fermentation–derived antibiotic, as the starting material. Macrolide will partner with Cempra to develop a fully synthetic, cost-competitive manufacturing process for solithromycin, which could provide manufacturing and supplier flexibility by reducing dependence on fermentation-derived starting materials.
 
Cempra will support research at Macrolide focused on the optimization, scalability and efficiency of a fully synthetic manufacturing approach. Macrolide will expand its process chemistry efforts to encompass the synthesis of solithromycin. The initial commercialization of solithromycin, if approved, will utilize the semi-synthetic process that begins with clarithromycin. Sometime later, a shift to a fully synthetic process could occur with validation and approval by the FDA. Financial terms were not disclosed.
 
“We are pleased with the current cost and feasibility of manufacturing solithromycin, but, if this new method is successful, we will have the option of decreasing our dependence on fermentation-derived clarithromycin, which may allow us to manage and control our manufacturing costs even further,” said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra.
 
“We are delighted to work with Cempra on solithromycin, a highly promising antibiotic and the only macrolide in late stage clinical development,” stated Lawrence G. Miller, M.D., CEO of Macrolide Pharmaceuticals.  “We have demonstrated our capability for a full synthesis of solithromycin, and this partnership will allow us to improve and extend this work.”

Related Contract Manufacturing:

Related Compliance:

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain

  • API Sourcing Trends

    API Sourcing Trends

    Kristin Brooks, Contract Pharma||March 19, 2015
    Ed Price of PCI Synthesis addresses trends, regulatory and supply chain hurdles, and quality concerns

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.